WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010123290) IN VIVO HALF LIFE INCREASED FUSION PROTEIN OR PEPTIDE MAINTAINED BY SUSTAINED IN VIVO RELEASE, AND METHOD FOR INCREASING IN VIVO HALF-LIFE USING SAME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/123290    International Application No.:    PCT/KR2010/002520
Publication Date: 28.10.2010 International Filing Date: 22.04.2010
IPC:
C07K 19/00 (2006.01), C07K 14/475 (2006.01), C07K 14/81 (2006.01)
Applicants: ALTEOGEN, INC [KR/KR]; 2nd Floor Gyeongbidong, Expo Science Park, 3-1 Doryong-dong, Yuseong-gu, Daejeon 305-340 (KR) (For All Designated States Except US).
CHUNG, Hye Shin [KR/KR]; (KR) (For US Only).
YOO, Seung Bum [KR/KR]; (KR) (For US Only).
LEE, Sang Mee [KR/KR]; (KR) (For US Only)
Inventors: CHUNG, Hye Shin; (KR).
YOO, Seung Bum; (KR).
LEE, Sang Mee; (KR)
Agent: ERUUM PATENT & LAW FIRM; 5F., Boseong Bldg., 1005-8 Daechi-dong, Kangnam-gu Seoul 135-851 (KR)
Priority Data:
10-2009-0035190 22.04.2009 KR
Title (EN) IN VIVO HALF LIFE INCREASED FUSION PROTEIN OR PEPTIDE MAINTAINED BY SUSTAINED IN VIVO RELEASE, AND METHOD FOR INCREASING IN VIVO HALF-LIFE USING SAME
(FR) PROTÉINE OU PEPTIDE DE FUSION DONT LA DEMI-VIE EST AUGMENTÉE PAR LE MAINTIEN DE LA LIBÉRATION PROLONGÉE IN VIVO, ET PROCÉDÉ D'AUGMENTATION DE LA DEMI-VIE IN VIVO EN L'UTILISANT
(KO) 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
Abstract: front page image
(EN)The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin mutant or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.
(FR)La présente invention concerne une protéine ou un peptide de fusion, dont la demi-vie in vivo est augmentée en maintenant une libération prolongée in vivo, et un procédé permettant d'augmenter la demi-vie in vivo utilisant ladite protéine/ledit peptide. La protéine ou le peptide de fusion selon la présente invention présente d'excellentes caractéristiques de stabilité in vivo en liant une protéine physiologiquement active ou un peptide physiologiquement actif à un mutant alpha-1 antitrypsine ou à un mutant alpha-1 antitrypsine ayant un ou plusieurs acides aminés mutés pour maintenir sa libération prolongée in vivo et pour augmenter de façon significative sa demi-vie dans le sang (T1/2) par comparaison avec une protéine physiologiquement active ou un peptide physiologiquement actif nature. Ainsi, une protéine ou un peptide de fusion selon la présente invention peut être utile dans le développement d'une préparation à libération prolongée d'un médicament à base de protéine ou de peptide.
(KO)본 발명은 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법에 관한 것이다. 본 발명에 따른 단백질 또는 펩티드 융합체는, 생리활성 단백질 또는 생리활성 펩티드를 알파-1 안티트립신 또는 하나 이상의 아미노산을 변이시킨 알파-1 안티트립신 변이체에 결합시켜 체내 지속성을 유지함으로 혈중반감기(T1/2)가 고유의 생리활성 단백질 또는 생리활성 펩티드보다 현저히 증가하여 체내 안정성이 우수하다. 따라서, 본 발명에 따른 단백질 또는 펩티드 융합체는 단백질 또는 펩티드 약물의 지속성 제제 개발에 유용하게 사용될 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)